These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6995131)

  • 1. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    Ledermann H; Kaufmann B
    J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    Anderson P; Norbeck HE
    Eur J Clin Pharmacol; 1981; 21(3):209-14. PubMed ID: 7318880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB; Marples J; Ledermann HM; Whittington J
    Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
    [No Abstract]   [Full Text] [Related]  

  • 5. "In vitro" metabolism of bezafibrate by rat liver.
    Maffei FR; Carini M; Bertuletti R; Tofanetti O
    Pharmacol Res Commun; 1981 Feb; 13(2):121-32. PubMed ID: 7220572
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
    Abshagen U; Kösters W; Kaufmann B; Lang PD
    Klin Wochenschr; 1980 Sep; 58(17):889-96. PubMed ID: 7442088
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of food on the absorption of the p-chlorophenolic ester of chlorophenoxyisobutyric acid in man.
    Houin G; Shastri RA; Barre J; Pinchon B; Tillement JP
    Br J Clin Pharmacol; 1984 Mar; 17(3):341-5. PubMed ID: 6712867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the metabolism of clofibride, a hypolipaemic drug.
    Loiseau GP; Millischer RJ; Lohier PY; Mardiguian JS; Gilede AM; Ginocchio AV
    J Pharm Pharmacol; 1980 Jul; 32(7):483-8. PubMed ID: 6105184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofibrate kinetics after single and multiple doses.
    Gugler R; Hartlapp J
    Clin Pharmacol Ther; 1978 Oct; 24(4):432-8. PubMed ID: 688733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 11. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P; Scheuermann E; Lang W
    Proc Eur Dial Transplant Assoc; 1981; 18():169-75. PubMed ID: 7036147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 13. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogs.
    Garrett ER; Altmayer P
    J Pharm Sci; 1985 Mar; 74(3):295-9. PubMed ID: 4009437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.
    Cayen MN; Ferdinandi ES; Greselin E; Robinson WT; Dvornik D
    J Pharmacol Exp Ther; 1977 Jan; 200(1):33-43. PubMed ID: 833760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of bezafibrate on biliary lipids (author's transl)].
    Schlierf G; Fischer H; Roche A; Stiehl A; Oster P; Schellenberg B; Vollmar J
    MMW Munch Med Wochenschr; 1980 Feb; 122(5):165-8. PubMed ID: 6767944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The short- and long-term effects of bezafibrate in the rat.
    Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
    Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent pharmacokinetics of clofibric acid in the non-human primate.
    Walmsley LM
    Arch Toxicol Suppl; 1984; 7():272-7. PubMed ID: 6595991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Walli AK; Seidel D
    Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.